IP Waiver Proposal Won’t Hold Back Moderna’s Rise

Bancel: 'IP Is Not The Issue'

 
• By Andrew McConaghie
  
The Moderna logo is seen at the Moderna campus in Norwood, Massachusetts on on December 2, 2020, where the biotechnology company is mass producing its Covid-19 vaccine.
Moderna has already booked advance sales of $19.2bn for its COVID-19 vaccine this year, with more to come. (JOSEPH PREZIOSO/AFP via Getty Images)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip